Butantan-DV 在 2-59 岁参与者中延长随访的有效性和安全性:巴西双盲、随机、安慰剂对照、3 期、多中心试验结果
该研究为巴西多中心 3 期双盲随机安慰剂对照试验,纳入 2-59 岁未接种过登革疫苗的健康人 16235 例,按 2:1 随机接受单剂 Butantan-DV 或安慰剂。平均随访 3.7 年,针对任何登革病毒血清型所致病毒学确诊登革(VCD)的疫苗有效性为 67.3%(95%CI 59.4-73.9),未观察到 DENV-3 或 DENV-4 所致病例,两组严重不良事件比例相似。
要点
- 单剂 Butantan-DV 对任何血清型所致 VCD 的疫苗有效性为 67.3%(95%CI 59.4-73.9)。
- 随访期间未观察到 DENV-3 或 DENV-4 所致 VCD 病例。
- 疫苗组严重不良事件 637 例(6.2%),安慰剂组 395 例(6.6%)。
核心结论
- 单剂 Butantan-DV 总体耐受良好,对登革病毒 1 型和 2 型所致症状性 VCD 在平均 3.7 年内有效。
- 这些发现支持继续开发 Butantan-DV 用于预防儿童、青少年和成人登革热,无论基线登革血清状态如何。
研究设计与样本
- 巴西双盲、随机、安慰剂对照、3 期、多中心试验,纳入 2-59 岁未接种过登革疫苗的健康参与者。
- 参与者按 2:1 随机分配接受 0.5 mL Butantan-DV(含四种疫苗病毒株各约 10^3 空斑形成单位)或安慰剂,皮下接种。
- 2016 年 2 月 22 日至 2019 年 7 月 5 日随机分配 16235 例,疫苗组 10259 例、安慰剂组 5976 例;符合方案人群 16162 例(疫苗组 10215 例、安慰剂组 5947 例),安全性人群 16235 例。
主要发现
- 截至 2021 年 7 月 13 日数据截止,随访 2-5 年(均值 3.7 年 [SD 1.0],中位 4.0 年 [IQR 3.2-4.5])。
- 随访期间共捕获 356 例 VCD,疫苗组 128 例、安慰剂组 228 例。
- 针对任何登革病毒血清型所致 VCD 的疫苗有效性为 67.3%(95%CI 59.4-73.9);未观察到 DENV-3 或 DENV-4 所致病例。
- 截至数据截止,疫苗组严重不良事件 637 例(6.2%),安慰剂组 395 例(6.6%),两组比例相似。
关键数值与推荐
- 主要终点为符合方案人群中接种后第 28 天起、无论基线登革血清状态、针对任何登革病毒血清型所致 VCD 的疫苗有效性。
临床怎么用
- 原文结论支持继续开发 Butantan-DV 用于预防儿童、青少年和成人登革热,无论登革血清状态如何。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A single-dose dengue vaccine that protects individuals across a wide age range and regardless of dengue serostatus is an unmet need. We assessed the safety and efficacy of the live, attenuated, tetravalent Butantan-dengue vaccine (Butantan-DV) in adults, adolescents, and children. We previously reported the primary and secondary efficacy and safety endpoints in the initial 2 years of follow-up. Here we report the results through an extended follow-up period, with an average of 3·7 years of follow-up. METHODS: In this double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil, healthy participants (aged 2-59 years) who had not previously received a dengue vaccine were enrolled and randomly assigned 2:1 (stratified by age 18-59 years, 7-17 years, and 2-6 years) using a central electronic randomisation system to receive 0·5 mL of Butantan-DV (containing approximately 103 plaque-forming units of each of the four vaccine virus strains) or placebo, administered subcutaneously. Syringes containing vaccine or placebo were prepared by an unmasked trial pharmacist who was not involved in any subsequent participant assessments; other site staff and the participants remained unaware of the group allocations. Vaccine efficacy was calculated with the accrual of virologically confirmed dengue (VCD) cases (by RT-PCR) at least 28 days after vaccination up until the cutoff (at least 2 years of follow-up from the last participant enrolled). The primary endpoint was vaccine efficacy against VCD after day 28 by any dengue virus (DENV) serotype regardless of dengue serostatus at baseline in the per-protocol population. The primary and secondary safety endpoints up until day 21 were previously reported; secondary safety endpoints include the frequency of unsolicited vaccine-related adverse events after day 22. Safety analyses were done on all participants as treated. This trial is registered with ClinicalTrials.gov (NCT02406729) and is ongoing. FINDINGS: Of 16 363 participants assessed for eligibility, 16 235 were randomly assigned between Feb 22, 2016, and July 5, 2019, and received single-dose Butantan-DV (10 259 participants) or placebo (5976 participants). 16 162 participants (Butantan-DV n=10 215; placebo n=5947) were included in the per-protocol population and 16 235 (Butantan-DV n=10 259; placebo n=5976) in the safety population. At the data cutoff (July 13, 2021), participants had 2-5 years of follow-up (mean 3·7 years [SD 1·0], median 4·0 years [IQR 3·2-4·5]). 356 VCD cases were captured through the follow-up (128 in the vaccine group and 228 in the placebo group). Vaccine efficacy against VCD caused by any DENV serotype was 67·3% (95% CI 59·4-73·9); cases caused by DENV-3 or DENV-4 were not observed. The proportions of participants who had serious adverse events were similar between treatment groups (637 [6·2%] in the vaccine group and 395 [6·6%] in the placebo group) up until the cutoff. INTERPRETATION: A single dose of Butantan-DV was generally well tolerated and efficacious against symptomatic VCD (caused by DENV-1 and DENV-2) for a mean of 3·7 years. These findings support the continued development of Butantan-DV to prevent dengue disease in children, adolescents, and adults regardless of dengue serostatus. FUNDING: Instituto Butantan and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co. TRANSLATIONS: For the Spanish and Portuguese translations of the abstract see Supplementary Materials section.
引用
- Nogueira ML, Cintra MAT, Moreira JA, et al. Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil. Lancet Infect Dis. 2024. PMID: 39116904. doi:10.1016/S1473-3099(24)00376-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。